Langdon Y, Tandon P, Paden E, Duddy J, Taylor JM, Conlon FL.

DE018825 NIDCR NIH HHS, HL075256-01S1 NHLBI NIH HHS , R01 HL089641 NHLBI NIH HHS , R01 HL075256 NHLBI NIH HHS , R01 DE018825 NIDCR NIH HHS

                Noonan syndrome with multiple lentigines
                Noonan syndrome
                acute lymphoblastic leukemia

           LYMPHOBLASTIC LEUKEMIA, ACUTE, WITH LYMPHOMATOUS FEATURES; LALL
           JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML

Xla Wt + ptpn11{N308D}(Fig. 1 FG)
Xla Wt + ptpn11{N308D}(Fig. 2 DJ)
Xla Wt + ptpn11{N308D}(Fig. 2 FL)
Xla Wt + ptpn11{N308D}(Fig. 3 B E)
Xla Wt + ptpn11{N308D}(Fig. 3 D E)
Xla Wt + ptpn11{N308D}(Fig. 4. B)
Xla Wt + ptpn11{N308D}(Fig. 4 D)
Xla Wt + ptpn11{N308D}(Fig. 4. FHJ)
Xla Wt + ptpn11{N308D}(Fig. 5 CFI)
Xla Wt + ptpn11{N308D}(Fig. 5 KM)
Xla Wt + ptpn11{N308D}(Fig. 7 C)
Xla Wt + ptpn11{N308D}(Fig. 7 C)
Xla Wt + ptpn11{N308D}(Fig. 7 GI)
Xla Wt + ptpn11{N308D}(Fig. S1 B)
Xla Wt + ptpn11{N308D,C459G}(Fig. 1 H)
Xla Wt + ptpn11{Q79R}(Fig. S1 D)

	Fig. 1. Noonan-associated mutation of SHP-2 leads to heart defects in Xenopus. (A) Schematic of SHP-2 constructs. Note that constructs used in Xenopus in vivo experiments were not epitope tagged with HA. (B) Western blot analysis of embryo lysates from embryos injected with the respective HA epitope-tagged SHP-2 constructs at stages 10 (gastrula), 16 (early neurula) and 26 (late neurula) probed with an anti-HA antibody, an anti-SHP-2 antibody that recognizes both endogenous and introduced versions of SHP-2, and an anti-EF-2 antibody as a loading control. (C-H) Whole-mount antibody staining of cleared stage 36 embryos with anti-tropomyosin antibody (Tmy). Anterior is to the left, posterior to the right. Scale bar: 100 μm. (I-Q) Whole-mount in situ hybridization of cleared stage 33 from uninjected (I,L,O), SHP-2FL (2 ng; J,M,P) and SHP-2N308D (2 ng; K,N,Q) embryos probed for Nkx2.5 (I-K), Tbx5 (L-N) or Tbx20 (O-Q). Scale bar: 1 mm. a, atrium; oft, outflow tract; v, ventricle.
	Fig. 2. 3D modeling of uninjected and SHP-2N308D cardiac tissue. (A-L) 3D modeling of Tmy expression in stage 29 (A,B,G,H), stage 33 (C,D,I,J) and stage 37 (E,F,K,L) Xenopus embryos. In A-F, hearts are viewed from anterior to posterior and red denotes the most anterior section of the heart. In G-L, hearts are viewed from the dorsal side. Arrows in A-F denote ends of cardiac trough. Note that in C the trough has closed across the dorsal midline in uninjected control but remains open in SHP-2N308D heart (2 ng; D). Edges of the trough come together by stage 37 (F) in the SHP-2N308D heart but have not closed across the ventral midline (arrows). Also, at stage 33 (J), the SHP-2N308D heart is much wider in anterior portions but is much thinner in posterior portions (arrows) versus corresponding control (I). Note the relative orientation of the outflow tract (o) to the inflow tract (i) in I versus J, indicative of a delay in looping. a, anterior; d, dorsal; p, posterior; v, ventral. Scale bars: 50 μm.
	Fig. 3. SHP-2N308D leads to a delay of the cardiac cell cycle. (A-D) Transverse heart sections through stage 33 (A,B) and stage 37 (C,D) Xenopus embryos stained with Tmy (green) and anti-phospho histone H3 (red), from uninjected (A,C) and SHP-2N308D-derived (B,D) embryos (2 ng). Scale bar: 50 μm. (E,F) Graphs representing total number of Tmy-positive cells (E) and the mitotic index (F) in SHP-2FL- (blue bars) and SHP-2N308D- (red bars) derived embryos at stages 29, 33 and 37. Bars represent the average of at least three embryos. Error bars represent s.d. *P≤0.05 (comparison of SHP-2FL and SHP-2N308D embryos).
	Fig. 4. A subpopulation of cardiac cells does not differentiate or incorporate into hearts of SHP-2N308D Xenopus embryos. (A-D) Transverse Toluidine Blue-stained histological sections of cardiac regions from stage 33 (A,B) and stage 37 (C,D) SHP-2FL (A,C) and SHP-2N308D (B,D) embryos (2 ng). c, unincorporated cardiac cells; E, endocardium; M, myocardium. Scale bar: 50 μm. (E-J) Transverse sections through stage 37 hearts of SHP-2FL (E,G,I) and SHP-2N308D (F,H,J) embryos (2 ng) stained with anti-MHC (green), anti-TBX5 (red) and DAPI (blue). Arrows mark TBX5 positive cells that have not incorporated into the heart. Scale bar: 50 μm.
	Fig. 5. SHP-2N308D leads to alterations in cardiac myofibril formation. (A-I) Transverse sections of stage 37 hearts from uninjected (A,D,G), SHP-2FL (B,E,H) or SHP-2N308D (C,F,I) Xenopus embryos (2 ng) immunostained for fibrillin (orange) and Tmy (green) (A-C), cardiac actin as detected by conjugated phalloidin (green; D-F) and tropomyosin (red) and DAPI (blue) (G-I). Scale bar: 100 μm. (J-M) Representative transmission electron micrographs of transverse images from stage 33 (J,K) or stage 37 (L,M) heart tissue derived from uninjected (J,L) or SHP-2N308D (L,M) embryos. Cardiac muscle fibrils are highlighted. Scale bars: 1 μm.
	Fig. 6. SHP-2N308D regulates actin deposition. (A-I) Cells were transfected with HA-SHP-2FL (A-C), HA-SHP-2N308D (D-F) or HA-SHP-2N308D-PTP (G-I), plated on FN and stained for phalloidin (red) (A,D,G), pY31 paxillin (green) (B,E,H), and HA (blue) to identify transfected cells (C,F,I). Arrows denote lamellipodia and focal adhesion complexes. (J) 2D cell area as a measure of cell spreading was calculated from 150-200 cells transfected with the designated construct, using ImageJ software tools. Error bars represent s.e.m.*P≤0.05. (K-R) Inhibition of ROCK activity rescues SHP-2N308D cell rounding phenotype. SHP-2N308D-transfected cells (blue; L,N,P,R) treated with Y27632 (O-R) for either 40 (O,P) or180 (Q,R) minutes displayed reduced actin arc formation and re-established focal adhesion complexes (arrows) compared with vehicle-treated cells (K-N). Scale bars: 10 μm.
	Fig. 7. ROCK inhibition rescues the cardiac morphogenetic defects seen in SHP-2N308D embryos. (A-D) Brightfield images of stage 40 Xenopus embryos from appropriate conditions. Note that pericardial edema in SHP-2N308D embryo (3.6 ng; C) is absent in sibling incubated with Y27632 (D) and uninjected controls (A,B). Scale bar: 2 mm. (E-H) Immunofluorescent images of cleared hearts stained with anti-MHC, indicating the rescue of cardiac malformation and looping defects in SHP-2N308D embryo (G) compared with sibling incubated in Y27632 (H) and uninjected controls (E,F). Scale bar: 100 μm. (I) Graph of percentage of normal heart morphology at stage 40 in control and SHP-2N308D sibling embryos treated with 10 μM ROCK inhibitor Y27632. Statistical significance is denoted as *P≤0.0001, **P=0.0002, ***P=0.0001 using Fisher’s exact two-tailed test. Anterior is to the left, posterior to the right in all images. a, atrium; oft, outflow tract; v, ventricle.
	Fig. S1. Associated Noonan syndrome mutations in SHP-2 lead to heart defects. Fluorescent images of anti-MHC-stained hearts from cleared stage 36 Xenopus embryos injected with SHP-2N308D (B), SHP-2D61G (C) or SHP-2Q79R (D) (3 ng) compared with uninjected controls (A). Anterior is to the left, posterior to the right. a, atrium; oft, outflow tract; v, ventricle. Scale bar: 100 .

Ahuja, Re-expression of proteins involved in cytokinesis during cardiac hypertrophy. 2007, Pubmed

Ahuja, Re-expression of proteins involved in cytokinesis during cardiac hypertrophy. 2007, Pubmed
Arber, Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. 1998, Pubmed
Bennett, Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. 1996, Pubmed
Bentires-Alj, Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. 2004, Pubmed
Brown, Small heat shock protein Hsp27 is required for proper heart tube formation. 2007, Pubmed , Xenbase
Burnette, A role for actin arcs in the leading-edge advance of migrating cells. 2011, Pubmed
Chang, Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. 2006, Pubmed
Digilio, Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. 2002, Pubmed
Doggrell, Rho-kinase inhibitors show promise in pulmonary hypertension. 2005, Pubmed
Feng, Shp-2 tyrosine phosphatase: signaling one cell or many. 1999, Pubmed
Fishman, Fashioning the vertebrate heart: earliest embryonic decisions. 1997, Pubmed
Fragale, Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. 2004, Pubmed
Fukata, Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. 1999, Pubmed
Georgescu, Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. 2000, Pubmed
Goetz, TBX5 is required for embryonic cardiac cell cycle progression. 2006, Pubmed , Xenbase
Hahn, Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. 2000, Pubmed
Harvey, Patterning the vertebrate heart. 2002, Pubmed
Haudek, Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. 2009, Pubmed
Iwamoto, Influence of ionic strength on the actomyosin reaction steps in contracting skeletal muscle fibers. 2000, Pubmed
Kolker, Confocal imaging of early heart development in Xenopus laevis. 2000, Pubmed , Xenbase
Kosaki, PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. 2002, Pubmed
Kosako, Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. 2000, Pubmed
Kratz, The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. 2005, Pubmed
Langdon, SHP-2 is required for the maintenance of cardiac progenitors. 2007, Pubmed , Xenbase
Lee, Regulation of RhoA-dependent ROCKII activation by Shp2. 2008, Pubmed
Legius, PTPN11 mutations in LEOPARD syndrome. 2002, Pubmed
Lin, Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. 2003, Pubmed
Loh, PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. 2004, Pubmed
Loirand, Rho kinases in cardiovascular physiology and pathophysiology. 2006, Pubmed
Maekawa, Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. 1999, Pubmed
Maheshwari, PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. 2002, Pubmed
Mohun, The morphology of heart development in Xenopus laevis. 2000, Pubmed , Xenbase
Mohun, The origins of cardiac tissue in the amphibian, Xenopus laevis. 2003, Pubmed , Xenbase
Musante, Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. 2003, Pubmed
Noonan, Noonan syndrome. An update and review for the primary pediatrician. 1994, Pubmed
Noonan, Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. 1968, Pubmed
Pawson, Tyrosine kinase signalling pathways. 1994, Pubmed
Qu, The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. 2000, Pubmed
Rikitake, Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. 2005, Pubmed
Saxton, Morphogenetic movements at gastrulation require the SH2 tyrosine phosphatase Shp2. 1999, Pubmed
Saxton, Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. 1997, Pubmed
Schildmeyer, Impaired vascular contractility and blood pressure homeostasis in the smooth muscle alpha-actin null mouse. 2000, Pubmed
Shea, ROCK1 and LIMK2 interact in spread but not blebbing cancer cells. 2008, Pubmed
Smith, Dorsalization and neural induction: properties of the organizer in Xenopus laevis. 1983, Pubmed , Xenbase
Tang, The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. 1995, Pubmed , Xenbase
Tartaglia, Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. 2003, Pubmed
Tartaglia, PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. 2002, Pubmed
Tartaglia, Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. 2001, Pubmed
Vahebi, Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. 2005, Pubmed
Van Vactor, Genetic analysis of protein tyrosine phosphatases. 1998, Pubmed
Wang, Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway. 2011, Pubmed
Wei, Rho kinases play an obligatory role in vertebrate embryonic organogenesis. 2001, Pubmed
Wilson, Induction of epidermis and inhibition of neural fate by Bmp-4. 1995, Pubmed , Xenbase
Yang, An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. 2006, Pubmed
Yokoyama, Aurora-B and Rho-kinase/ROCK, the two cleavage furrow kinases, independently regulate the progression of cytokinesis: possible existence of a novel cleavage furrow kinase phosphorylates ezrin/radixin/moesin (ERM). 2005, Pubmed
Zhang, Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. 2000, Pubmed
Zhao, Rho-associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation. 2003, Pubmed